• OUTLOOK ARENA
  • VIEWS ON NEWS
  • OCTOBER 28, 2003

GSK Pharma: Efficiencies drive growth

GlaxoSmithKline Pharma (GSK) has announced its 3QFY04 results. Despite a revival in the domestic pharma market, the company has posted a meager 4% growth in topline (GSK had recorded an impressive 10% growth during 2QFY04 when the domestic pharma industry was going through a tough phase). However, improvement in operating efficiencies has helped the company record a robust 55% growth in bottomline. For 9mFY04, GSK has reported a 4% growth in net sales and a 56% rise in net profit.

Results at a glance…
(Rs m)3QFY033QFY04Change9mFY039mFY04Change
Net Sales2,9743,1044.4%8,3648,7074.1%
Other Income141.8152.77.7%30738324.7%
Total expenditure2,4352,325-4.5%6,8566,682-2.5%
Operating Profit (EBDIT)53977944.6%1,5082,02534.3%
Operating Profit Margin (%)18.1%25.1% 18.0%23.3% 
Depreciation5543-21.9%149131-12.1%
Profit before Tax62688942.1%1666227736.7%
Extra-ordinary items(21)0  (53)123 
Tax23231234.6%60482536.6%
Profit after Tax/(Loss)37457754.5%1,0101,57556.0%
Net profit margin (%)12.6%18.6% 12.1%18.1% 
No. of Shares (m)74.574.5 74.574.5 
Earnings per share*20.131.0 18.128.2 
P/E ratio 14.9  16.4 
*(annualised)      

GSK managed to marginally outperform the industry growth rate during the periods under review. The company continued to reap rich dividends from its strategy of concentrating on few power brands the demand for which remained strong, resulting in a double-digit growth in the power brands portfolio. However, the cessation of ‘Ranitidine’ exports resulted in a 45% dip in export revenues, which put pressure on the topline.

However, despite slow topline growth, GSK managed to record strong growth in operating profits. This was primarily on account of higher sales of profitable brands and tight control over expenditure resulting in a 700-basis points improvement in operating profit margins. This coupled with a rise in other income (due to higher interest income), lower depreciation provision and extra-ordinary items have helped the company record a strong growth in bottomline. It is to be noted here that extra-ordinary expense during 9mFY03 relates to VRS and separation charges incurred by the company, while, extra-ordinary income during 9mFY04 relates to profit on sale of its property in Bangalore. The sale of GSK’s Mumbai property is expected to further strengthen the company’s cash flows.

Recognizing the growth potential in the domestic market with the implementation of product patents post 2005, GSK has decided to gradually launch new products. The company plans to make three new product launches every year. GSK is also planning to enter the high margin chronic areas of CNS and diabetes. The company is also aiming at bringing about a 50% improvement in its sales force efficiency by 2005.

At Rs 462, GSK is trading at a P/E of 16x its annualised 9mFY04 earnings. Although GSK plans to foray into the lifestyle segment, limited exposure in the same and high DPCO cover remain a cause for concern. However, in view of the impending implementation of product patent, the strategy adopted by the company for preparing itself for the same, its market leadership position and access to parent’s strong product portfolio, we remain positive about the long-term prospects of the company.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407